Rapid Progress in Bench-to-Clinic Reported for Several Cancers

The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.

A second investigational drug in the isocitrate dehydrogenase (IDH) inhibitor class has demonstrated activity in acute myeloid leukemia (AML), a small clinical study showed.

Seven of 14 patients with relapsed or refractory AML had objective responses to treatment with AG-120, an orally available inhibitor of IDH1. The clinical activity included four complete responses.

The drug has been well tolerated during the ongoing phase I trial to identify the optimal dose for continued clinical evaluation, Daniel Pollyea, MD, assistant professor of medicine at the University of Colorado in Denver, reported at the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

Earlier this year, another small phase I study showed activity with the IDH2 inhibitor AG-221, which resulted in objective responses in six of seven patients with relapsed or refractory AML.

Link to the report on Medpage Today: http://bit.ly/1I9dX4R